| scholarly article | Q13442814 |
| P50 | author | Scott B. Patten | Q37393357 |
| Raymond W. Lam | Q42883552 | ||
| Sidney H. Kennedy | Q59560583 | ||
| P2093 | author name string | Sagar V Parikh | |
| Arun V Ravindran | |||
| P921 | main subject | major depressive disorder | Q42844 |
| P304 | page(s) | S1-2 | |
| P577 | publication date | 2009-08-13 | |
| P1433 | published in | Journal of Affective Disorders | Q15716493 |
| P1476 | title | Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction | |
| P478 | volume | 117 Suppl 1 |
| Q36371830 | A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada From 2006 to 2012. |
| Q63544973 | A Primary Care Perspective on Prescribing for Women |
| Q48037730 | A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder |
| Q57480223 | Alterations in patients with major depressive disorder before and after electroconvulsive therapy measured by fractional amplitude of low-frequency fluctuations (fALFF) |
| Q35601849 | Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study |
| Q33903464 | Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. |
| Q48212851 | Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report |
| Q36588685 | Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis |
| Q38109590 | Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder |
| Q38003196 | Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder |
| Q60934498 | Benzodiazepine receptor agonist dispensations in Alberta: a population-based descriptive study |
| Q48439687 | C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy |
| Q37197203 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods |
| Q37197211 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care |
| Q37197221 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. |
| Q37197216 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments |
| Q37197230 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. |
| Q37197207 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. |
| Q40424748 | Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression |
| Q94338217 | Continuation and maintenance treatments for persistent depressive disorder |
| Q37827221 | Depression in the workforce: the intermediary effect of medical comorbidity. |
| Q36395440 | Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups |
| Q34393030 | Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder |
| Q60619777 | Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study |
| Q38476909 | Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. |
| Q37940736 | Evidence-based medicine: opportunities and challenges in a diverse society |
| Q64256919 | Examining postpartum depression screening effectiveness in well child clinics in Alberta, Canada: A study using the All Our Families cohort and administrative data |
| Q38949762 | Formative evaluation of practice changes for managing depression within a Shared Care model in primary care |
| Q38126094 | Getting depression clinical practice guidelines right: time for change? |
| Q27313782 | How do general practitioners contribute to preventing long-term work disability of their patients suffering from depressive disorders? A qualitative study |
| Q64232538 | Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment |
| Q41474591 | Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines. |
| Q37617268 | Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines |
| Q40929485 | Manpower requirements for medical doctors in psychiatric departments of community hospitals--bottom-up calculation for the psychiatric department of Donauspital in Vienna |
| Q33815733 | MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes |
| Q34322113 | Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression |
| Q47604739 | Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement |
| Q64880287 | Multinational comparison of new antidepressant use in older adults: a cohort study. |
| Q37429825 | Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability |
| Q38300369 | Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies |
| Q38007306 | Postpartum depression: diagnostic and treatment issues |
| Q31121504 | Predicting chronic benzodiazepine use in adults with depressive disorder: Retrospective cohort study using administrative data in Quebec |
| Q33779403 | Pretreatment brain states identify likely nonresponse to standard treatments for depression |
| Q34993164 | Prevalence of and factors related to the use of antidepressants and benzodiazepines: results from the Singapore Mental Health Study |
| Q61635299 | Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment |
| Q35849773 | Reasons and Determinants for Perceiving Unmet Needs for Mental Health in Primary Care in Quebec |
| Q36684274 | Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era. |
| Q36591265 | Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode |
| Q38192967 | Role of lithium augmentation in the management of major depressive disorder |
| Q37635714 | Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults |
| Q36137019 | Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. |
| Q33552055 | The 2014 Survey on Living with Chronic Diseases in Canada on Mood and Anxiety Disorders: a methodological overview |
| Q37784203 | The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. |
| Q37974998 | The hidden third: improving outcome in treatment-resistant depression |
| Q39021956 | Therapeutics of postpartum depression |
| Q35549737 | Toward a neuroimaging treatment selection biomarker for major depressive disorder |
| Q33954188 | Treating concurrent chronic low back pain and depression with low-dose venlafaxine: an initial identification of "easy-to-use" clinical predictors of early response |
| Q48029414 | Under-diagnosis of mood disorders in Canada. |
| Q38300376 | Understanding the role of adjunctive nonpharmacological therapies in management of the multiple pathways to depression |
| Q26766211 | Update on Neuromodulation for Treatment-Resistant Depression |
| Q42339068 | Updated CANMAT Guidelines for Treatment of Major Depressive Disorder |
| Q33744537 | Use of antidepressants during pregnancy: a better choice for some |
| Q38792168 | Use of medication and psychological counselling among Canadians with mood and/or anxiety disorders |
| Q47740487 | Wake and light therapy for moderate-to-severe depression - a randomized controlled trial. |
| Q34474435 | What is depression? Psychiatrists' and GPs' experiences of diagnosis and the diagnostic process |
| Q35560309 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. |
| Q86705245 | [Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part I: Risk Factors, |
| Q86705250 | [Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part II: General Aspec |
Search more.